A MULTICENTRE, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED PHASE 3 EFFICACY AND SAFETY STUDY OF BENRALIZUMAB FOR THE PREVENTION OF RECURRENCE OF NASAL POLYPS FOLLOWING SURGICAL REMOVAL IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (OXALIS)

Registry ID
D3252C00004
Source registry
HEALTH_CANADA
Status
Pending
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
ASTRAZENECA CANADA INC
Last update
2020-06-30

Conditions

Related clinical trials

View on source registry